索拉非尼治疗肝细胞癌过程中出现坏死性血管炎伴脂膜炎，病情进展。
A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression.
机构信息
1 Department of Oncology and Advanced Technologies, Oncology Unit, 2 Department of Oncology and Advanced Technologies, Patology Unit, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.
出版信息
J Gastrointest Oncol. 2014 Dec;5(6):E121-4. doi: 10.3978/j.issn.2078-6891.2014.079.
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and is the third most common cause of death from cancer. Sorafenib is the only drug which improves survival in first line advanced HCC. Sorafenib has been associated with several dermatologic toxicities and toxic effects have been related to a better treatment response. We report the case of a well-circumscribed panniculitis and necrotizing vasculitis due to sorafenib, appeared in disease progression in a man affected by advanced HCC.
摘要
肝细胞癌（HCC）是全球第六大常见癌症，也是癌症死亡的第三大主要原因。索拉非尼是唯一能改善晚期 HCC 一线治疗患者生存的药物。索拉非尼与多种皮肤毒性有关，并且毒性作用与更好的治疗反应有关。我们报告了一例由索拉非尼引起的界限清楚的脂膜炎和坏死性血管炎，出现在一名患有晚期 HCC 疾病进展的患者中。
相似文献
1
A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression.
J Gastrointest Oncol. 2014 Dec;5(6):E121-4. doi: 10.3978/j.issn.2078-6891.2014.079.
2
Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Indian J Cancer. 2017 Jul-Sep;54(3):526-529. doi: 10.4103/ijc.IJC_373_17.
3
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Cell Physiol Biochem. 2017;44(2):716-727. doi: 10.1159/000485285. Epub 2017 Nov 23.
4
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.
Crit Rev Oncol Hematol. 2014 Jul;91(1):1-8. doi: 10.1016/j.critrevonc.2013.12.013. Epub 2014 Jan 7.
5
Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.
Mol Clin Oncol. 2017 Mar;6(3):389-396. doi: 10.3892/mco.2017.1132. Epub 2017 Jan 16.
6
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Aliment Pharmacol Ther. 2017 Apr;45(8):1146-1155. doi: 10.1111/apt.13977. Epub 2017 Mar 2.
7
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
JMIR Res Protoc. 2018 Aug 15;7(8):e11234. doi: 10.2196/11234.
8
Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Oncotarget. 2017 May 2;8(18):29771-29784. doi: 10.18632/oncotarget.15967.
9
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Hepatol Int. 2017 Mar;11(2):199-208. doi: 10.1007/s12072-016-9774-x. Epub 2016 Dec 1.
10
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6.
引用本文的文献
1
Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment-Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives.
Life (Basel). 2024 Aug 25;14(9):1062. doi: 10.3390/life14091062.
2
Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature.
Exp Ther Med. 2019 Feb;17(2):1128-1131. doi: 10.3892/etm.2018.6988. Epub 2018 Nov 19.
3
Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience.
J Korean Med Sci. 2018 Feb 12;33(7):e55. doi: 10.3346/jkms.2018.33.e55.
本文引用的文献
1
Sorafenib and sunitinib: A dermatologist's perspective.
Indian Dermatol Online J. 2014 Jan;5(1):1-3. doi: 10.4103/2229-5178.126017.
2
Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.
Eur J Clin Pharmacol. 2013 Oct;69(10):1819-26. doi: 10.1007/s00228-013-1532-6. Epub 2013 Jun 9.
3
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
4
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
5
Sorafenib in advanced clear-cell renal-cell carcinoma.
N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655.
6
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74. doi: 10.1007/s00280-006-0393-4. Epub 2006 Dec 8.
7
Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.
Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47. doi: 10.1111/j.1365-2036.2006.02932.x.
8
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Eur J Cancer. 2006 Mar;42(4):548-56. doi: 10.1016/j.ejca.2005.11.014. Epub 2006 Jan 19.
9
Management of hepatocellular carcinoma.
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
10
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443.
Zotero 插件